<DOC>
	<DOC>NCT00671073</DOC>
	<brief_summary>This study will assess the safety and efficacy of a range of oglemilast doses. The study will be 14 weeks in duration. All patients meeting the eligibility criteria will be randomized to one of three doses of oglemilast or placebo.</brief_summary>
	<brief_title>Study To Assess Efficacy and Safety of Oglemilast in Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<criteria>Presence of COPD as defined by GOLD criteria (2006); postbronchodilator FEV1/FVC &lt;70%, and postbronchodilator FEV1 &gt;30% and &lt; 80% predicted Current or former cigarette smoker Longterm oxygen use of &gt; 15 hours a day Symptoms consistent with a significant asthmatic component (e.g. atopic disease, allergic symptoms) Any COPD exacerbations within 30 days prior to study entry or during runin History of chronic or recurrent gastrointestinal disorder associated with bleeding in previous 12 months Presence of clinical significant pulmonary disease other than COPD</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Airflow Obstruction, Chronic</keyword>
	<keyword>Chronic Airflow Obstruction</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>Chronic Obstructive Airway Disease</keyword>
	<keyword>Chronic Obstructive Lung Disease</keyword>
	<keyword>COPD</keyword>
	<keyword>COAD</keyword>
</DOC>